Design and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept (Twincer®) for high powder doses

被引:65
作者
de Boer, Anne H.
Hagedoorn, Paul
Westerman, Elsbeth M.
Le Brun, Paul P. H.
Heijerman, Harry G. M.
Frijlink, Henderik W.
机构
[1] Univ Groningen, Dept Pharmaceut Technol & Biopharm, NL-9713 AV Groningen, Netherlands
[2] Cent Hosp Pharm, The Hague, Netherlands
[3] HagaHosp, Adult Cyst Fibrosis Ctr, The Hague, Netherlands
关键词
antibiotics; cystic fibrosis (CF); dry powder inhaler; multiple air classifier technology; sweeper crystals; Twincer (R);
D O I
10.1016/j.ejps.2005.11.013
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Dry powder inhalation of antibiotics in cystic fibrosis (CF) therapy may be a valuable alternative for wet nebulisation, because it saves time and it improves lung deposition. In this study, it is shown that the use of multiple air classifier technology enables effective dispersion of large amounts of micronised powder (up to 25 mg). X-50-values of the aerosol from laser diffraction analysis obtained with the Twincer((R)) disposable inhaler concept (containing multiple air classifier technology) are practically the same as that for the pure drug in the range of dose weights between 0 and 25 mg. Only for the highest dose weights, a minor fraction (5-7.5%) of small agglomerates (S-15 mu m) is released from the inhaler. Moreover, the size distribution of the aerosol is practically the same at 1 and 4 kPa. Cascade impactor results confirm the good performance of the multiple classifier concept. Unprocessed micronised particles or soft spherical agglomerates can be used, and special particle engineering processes are not necessary. Only a minor fraction of coarse sweeper crystals in the formulation is desired to reduce the total inhaler losses for colistin sulfomethate to less than 5-6% at 4 kPa. The classifiers can be designed to retain these crystals with more than 95% efficiency. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:171 / 178
页数:8
相关论文
共 35 条
[1]  
[Anonymous], EUR RESP REV
[2]  
Boer A.H. de, 2004, Eur. Patent Application, Patent No. 1488819
[3]   Design and application of a new modular adapter for laser diffraction characterization of inhalation aerosols [J].
de Boer, AH ;
Gjaltema, D ;
Hagedoorn, P ;
Schaller, M ;
Witt, W ;
Frijlink, HW .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 249 (1-2) :233-245
[4]   Air classifier technology (ACT) in dry powder inhalation - Part I. Introduction of a novel force distribution concept (FDC) explaining the performance of a basic air classifier on adhesive mixtures [J].
de Boer, AH ;
Hagedoorn, P ;
Gjaltema, D ;
Goede, J ;
Frijlink, HW .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2003, 260 (02) :187-200
[5]   Dry powder inhalation of antibiotics in cystic fibrosis therapy, part 1: development of a powder formulation with colistin sulfate for a special test inhaler with an air classifier as de-agglomeration principle [J].
de Boer, AH ;
Le Brun, PPH ;
van der Woude, HG ;
Hagedoorn, P ;
Heijerman, HGM ;
Frijlink, HW .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2002, 54 (01) :17-24
[6]   Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomised trial [J].
Dilraj, A ;
Cutts, FT ;
de Castro, JF ;
Wheeler, JG ;
Brown, D ;
Roth, C ;
Coovadia, HM ;
Bennett, JV .
LANCET, 2000, 355 (9206) :798-803
[7]   Barriers to and new approaches for gene therapy and gene delivery in cystic fibrosis [J].
Ferrari, S ;
Geddes, DM ;
Alton, EWFW .
ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (11) :1373-1393
[8]  
FLYNN RA, 2000, Patent No. 0016745
[9]  
Gerrity T. R., 1990, RESP DRUG DELIVERY, P1
[10]   INHALED MICRONIZED GENTAMICIN POWDER - A NEW DELIVERY SYSTEM [J].
GOLDMAN, JM ;
BAYSTON, SM ;
OCONNOR, S ;
MEIGH, RE .
THORAX, 1990, 45 (12) :939-940